TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment of refractory AML
Source: Childhood Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 15, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Recurrent or Refractory Childhood AML / Refractory Childhood AML (Induction Failure)
Treatment options for children with refractory AML may include the following:
Chemotherapy with HSCT.
Source links and citations
Immunotherapeutic approaches (gemtuzumab ozogamicin).
Source links and citations
Continue within this section
Preserved source evidence · Not medical advice